ABSTRACT
Kidney involvement in cancer patients is an increasing problem that needs more complex, collaborative and specialized care. Increasing number of patients are treated with new classes of medications that predispose them to kidney injury. With increasing the population age of cancer patients who are already at increased risk for kidney disease, emerging kidney toxicities associated with drugs targeting VEGF and other signaling pathways are problems that nowadays we are facing for management of these patients. Myeloma- associated kidney disease, cancer and treatment-related microangiopathies and glomerulonephritis, stem cell transplant-associated kidney injuries, all are exciting and expanding horizons in this field
ABSTRACT
Kidney Disease has been known to be associated with bone abnormal early as 1883.Despite of the emergence of new and more inclusive terms low turnover and high definition still are useful definitions Aluminum toxicity also is threat among these patients The study was started on 30 patients recruited from several hemodialysis. Units in Tabriz. SIX patients left the study and only 24 patients completed their work up [10 female and 4 males] Immunoradionsetric assay was used to measure the bone specific alkaline phosphatase [BAP] and intact parathyroid hormone [I PTH]. Serum Aluminum was studied by atomic absorption In 8 patients [8124, 33%] serum level of iPTH was lower than 150pg/ml, and in 14 patients [14124, 58%] serum BAP levels was lower than 27 U/L, but only in 5 patients [5/24, 20%] the combination of low iPTH [